Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7867-7881

  Dolman, Nigel P ^a   Troop, Helen M ^a   More, Julia C A ^a   Alt, Andrew ^b   Knauss, Jody L ^b   Nistico, Robert ^a   Jack, Samantha ^a   Morley, Richard M ^a   Bortolotto, Zuner A ^a   Roberts, Peter J ^a   Bleakman, David ^b   Collingridge, Graham L ^a   Jane, David E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 AMINO 2 CARBOXYETHYL) 3 (2 CARBOXYBENZYL) 5 IODOPYRIMIDINE 2,4 DIONE; 1 (2 AMINO 2 CARBOXYETHYL) 3 (2 CARBOXYBENZYL)PYRIMIDINE 2,4 DIONE; 1 (2 AMINO 2 CARBOXYETHYL) 3 (4 CARBOXYBENZYL)PYRIMIDINE 2,4 DIONE; 5 IODOWILLARDIINE; 6 (4 CARBOXYBENZYL) 1,2,3,4,4A,5,6,7,8,8A DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; GLUTAMIC ACID; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR ANTAGONIST; NATURAL PRODUCT; NS 3763; UNCLASSIFIED DRUG; WILLARDIINE;

ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT; SPINAL CORD;

ALANINE; ANIMALS; ANIMALS, NEWBORN; CALCIUM; CELL LINE; HUMANS; LONG-TERM POTENTIATION; MOSSY FIBERS, HIPPOCAMPAL; NERVE FIBERS, UNMYELINATED; PROTEIN SUBUNITS; PYRIMIDINONES; RADIOLIGAND ASSAY; RATS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECOMBINANT PROTEINS; SPINAL CORD; SPINAL NERVE ROOTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 28244465987     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050584l     Document Type: Article

References (73)

1. (a) Watkins, J. C.; Krogsgaard-Larsen, P.; Honoré, T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 1990, 11, 25-33.
2. (b) Jane, D. E. Antagonists acting at the NMDA receptor complex: potential for therapeutic applications. In Glutamate and GABA receptors and transporters; Krogsgaard-Larsen, P., Egebjerg, J., Schousboe, A., Eds.; Taylor and Francis: London, 2002; pp 69-98.
3. (c) Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
4. (a) Fletcher, E. J.; Lodge, D. New developments in the molecular pharmacology of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors. Pharmacol. Ther. 1996, 70, 65-89.
5. (b) Bleakman, D.; Lodge, D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998, 37, 1187-1204.
6. (c) Jane, D. E.; Tse, H.-W.; Skifter, D. A.; Christie, J. M.; Monaghan, D. T. Glutamate receptor ion channels: Activators and inhibitors. In Pharmacology of Ionic Channel Function: Activators and Inhibitors; Endo, M., Kurachi Y., Mishina, M., Eds.; Springer-Verlag: Berlin, 2000; pp 415-459.
7. (a) Bettler, B.; Mulle, C. Neurotransmitter receptors. 2. AMPA and kainate receptors. Neuropharmacology 1995, 34, 123-139.
8. (b) Chittajallu, R.; Braithwaite, S. P.; Clarke, V. R.; Henley, J. M. Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol. Sci. 1999, 20, 26-35.
9. (c) Lodge, D.; Dingledine, R. Ionotropic Glutamate Receptors. The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed.; IUPHAR Media Ltd: London, 2001.
10. (a) Clarke, V. R.; Ballyk, B. A.; Hoo, K. H.; Mandelzys, A.; Pellizzari, A.; Bath, C. P.; Thomas, J.; Sharpe, E. F.; Davies, C. H.; Ornstein, P. L.; Schoepp, D. D.; Kamboj, R. K.; Collingridge, G. L.; Lodge, D.; Bleakman, D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 1997, 389, 599-603.
11. (b) Vignes, M.; Clarke, V. R.; Parry, M. J.; Bleakman, D.; Lodge, D.; Ornstein, P. L.; Collingridge, G. L. The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. Neuropharmacology 1998, 37, 1269-1277.
12. (c) Bortolotto, Z. A.; Clarke, V. R.; Delany, C. M.; Parry, M. C.; Smolders, I.; Vignes, M.; Ho, K. H.; Miu, P.; Brinton, B. T.; Fantaske, R.; Ogden, A.; Gates, M.; Ornstein, P. L.; Lodge, D.; Bleakman, D.; Collingridge, G. L. Kainate receptors are involved in synaptic plasticity. Nature 1999, 402, 297-301.
13. (d) Filla, S. A.; Winter, M. A.; Johnson, K. W.; Bleakman, D.; Bell, M. G.; Bleisch, T. J.; Castano, A. M.; Clemens-Smith, A.; Del Prado, M.; Dieckman, D. K.; Dominguez, E.; Escribano, A.; Ho, K. H.; Hudziak, K. J.; Katofiasc, M. A.; Martinez-Perez, J. A.; Mateo, A.; Mathes, B. M.; Mattiuz, E. L.; Ogden, A. M. L.; Phebus, L. A.; Stack, D. R.; Stratford, R. E.; Ornstein, P. L. Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3- carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J. Med. Chem. 2002, 45, 4383-4386.
14. (a) O'Neill, M. J.; Bond, A.; Ornstein, P. L.; Ward, M. A.; Hicks, C. A.; Hoo, K.; Bleakman, D.; Logde, D. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 1998, 37, 1211-1222.
15. (b) Simmons, R. M. A.; Li, D. L.; Hoo, K. H,; Deverill, M.; Ornstein, P. L.; Iyengar, S. Kainate GluR5 receptor mediates the nociceptive response to formalin in the rat. Neuropharmacology 1998, 37, 25-36.
16. (c) O'Neill, M. J.; Bogaert, L.; Hicks, C. A.; Bond, A.; Ward, M. A.; Ebinger, G.; Ornstein, P. L.; Michotte, Y.; Lodge, D. LY377770, a novel iGluR5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology 2000, 39, 1575-1588.
17. K5-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat. Neurosci. 2002, 5, 796-804.
18. K5 receptors. J. Pharmacol. Exp. Ther. 2004, 309, 1003-1010.
19. (b) Valgeirsson, J.; Nielsen, E. Ø.; Peters, D.; Kristensen, A. S.; Madsen, U. Bioisosteric Modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J. Med. Chem. 2004, 47, 6948-6957.
20. (a) Jane, D. E.; Pook, P. C.-K.; Sunter, D. C.; Udvarhelyi, P. M.; Watkins, J. C. New willardiine analogs with potent stereoselective actions on mammalian spinal neurones. Br. Pharmacol. 1991, 104, 333P.
21. (b) Blake, J. F.; Jane, D. E.; Watkins, J. C. Action of willardiine analogs on immature rat dorsal roots. Br. J. Pharmacol. 1991, 104, 334P.
22. (c) Patneau, D. K.; Mayer, M. L.; Jane, D. E.; Watkins, J. C. Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J. Neurosci. 1992, 12, 595-606.
23. (d) Wong, L. A.; Mayer, M. L.; Jane, D. E.; Watkins, J. C. Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J. Neurosci. 1994,14, 3881-3897.
24. (e) Hawkins, L. M.; Beaver, K. M.; Jane, D. E.; Taylor, P. M.; Sunter, D. C.; Roberts, P. J. Binding of the new radioligand (S)-[3H]-AMPA to rat-brain synaptic membranes-effects of a series of structural analogs of the non-NMDA receptor agonist willardiine. Neuropharmacology 1995, 34, 405-410.
25. (f) Hawkins, L. M.; Beaver, K. M.; Jane, D. E.; Taylor, P. M.; Sunter, D. C.; Roberts, P. J. Characterization of the pharmacology and regional distribution of (S)-[3H]-5-fluorowillardiine binding in rat brain. Br. J. Pharmacol. 1995, 116, 2033-2039.
26. (g) Hawkins, L. M.; Jane, D. E.; Roberts, P. J. The effect of 6-aza substitution on the affinity of willardiine derivatives for the AMPA receptor. Br. J. Pharmacol Proc. Suppl. 1995, 117, 332P.
27. (h) Thompson, G. A.; Jane, D. E.; Watkins, J. C. Depolarising effects of certain derivatives of (S)-willardiine upon in vitro neonatal rat dorsal roots. Br. J. Pharmacol. Proc. Suppl. 1995, 117, 331P.
28. Jane, D. E.; Hoo, K.; Kamboj, R.; Deverill, M.; Bleakman, D.; Mandelzys, A. Synthesis of Willardiine and 6-Azawillardiine analogs: Pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J. Med. Chem. 1997, 40, 3645-3650.
29. Madsen, U.; Bang-Andersen, B.; Brehm, L.; Christensen, I. T.; Ebert, B.; Kristoffersen, Y. L.; Krogsgaard-Larsen, P. Synthesis and pharmacology of highly selective carboxy and phosphono isoxazole amino acid AMPA receptor antagonists. J. Med. Chem. 1996, 39, 1682-1691.
30. (a) Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Leander, J. D.; Schoepp, D. D. (3SR,4aRS,6RS,8aRS)-6-[2(1HTetrazol-5-yl)ethyl] decahydroisoquinoline-3-carboxylic Acid: A Structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem. 1993, 36, 2046-2048.
31. (b) Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution. J. Med. Chem. 1996, 39, 2219-2231.
32. (c) Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic Acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity. J. Med. Chem. 1996, 39, 2232-2244.
33. (a) More, J. C. A.; Troop, H. M.; Jane, D. E. The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. Br. J. Pharmacol. 2002, 137, 1125-1133.
34. (b) More, J. C. A.; Troop, H. M.; Dolman, N. P.; Jane, D. E. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br. J. Pharmacol. 2003, 138, 1093-1100.
35. (c) More, J. C. A.; Nistico, R.; Dolman, N. P.; Clarke, V. R. J.; Alt, A. J.; Ogden, A. M.; Buelens, F. P.; Troop, H. M.; Kelland, E. E.; Pilato, F.; Bleakman, D.; Bortolotto, Z. A.; Collingridge, G. L.; Jane, D. E. Characterisation of UBP296; a novel, potent and selective kainate receptor antagonist. Neuropharmacology 2004, 47, 46-64.
36. Hilbert, G. E.; Jansen, E. F. Action of alkali on 2,4-diethoxypyrimidine and the application of the reaction to a new synthesis of cytosine. J. Am. Chem. Soc. 1935, 57, 552-554.
37. 1-pyrimidyl)-2-aminobutyric Acids. Tetrahedron 1968, 25, 5989-5994.
38. (a) Arnold, L. D.; Drover, J. C. G.; Vederas, J. C. Conversion of serine beta-lactones to chiral alpha amino acids by copper-containing organolithium and organomagnesium reagents. J. Am. Chem. Soc. 1987, 109, 4649-4659.
39. (b) Arnold, L. D.; Kalantar, T. H.; Vederas, J. C. Conversion of serine to stereochemically pure β-substituted α-amino acids via β-lactones. J. Am. Chem. Soc. 1985, 107, 7105-7109.
40. (c) Ramer, S. E.; Moore, R. N.; Vederas, J. C. Mechanism of formation of serine β-lactones by Mitsunobu cyclization: synthesis and use of L-serine stereospecifically labelled with deuterium at C-3. Can. J. Chem. 1986, 64, 706-713.
41. Novacek, A.; Lissnerova, M. Nucleic acid components and their analogues. CVII. Cyanoethylation of uracil and 2-thiouracil derivatives. Collect. Czech. Chem. Commun. 1968, 33, 604-609.
42. Robins, M. J.; Barr, P. J.; Giziewicz, J. Nucleic acid related compounds. 38. Smooth and high yield iodination and chlorination at C-5 of uracil bases and p-tolyl-protected nucleosides. J. Can. Chem. 1982, 60, 554-557.
43. Agrawal, S. G.; Evans, R. H. The primary afferent depolarizing action of kainate in the rat. Br. J. Pharmacol. 1986, 87, 345-355.
44. (a) Bettler, B.; Boulter, J.; Hermans-Borgmeyer, I.; O'Shea-Greenfield, A.; Deneris, E. S.; Moll, C.; Borgmeyer, U.; Hollman, M.; Heinemann, S. Cloning of a novel glutamate receptor subunit, GluR5: expression in the central nervous system during development. Neuron 1990, 5, 583-595.
45. (b) Wilding, T. J.; Huettner, J. E. Functional diversity and developmental changes in rat neuronal kainate receptors. J. Physiol. 2001, 532.2, 411-421.
46. (c) Kerchner, G. A.; Wilding, T. J., Huettner, J. E.; Zhuo, M. Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. J. Neurosci. 2002, 22, 8010-8017.
47. 3H]-5-fluorowillardiine binding in rat brain. Br. J. Pharmacol. 1995, 116, 2033-2039.
48. 3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes. Neuropharmacology 1997, 36, 1483-1488.
49. (a) Lomeli, H.; Wisden, W.; Kohler, M.; Keinanen, K.; Sommer, B.; Seeburg, P. H. High-affinity kainate and domoate receptors in rat brain. FEBS Lett. 1992, 307, 139-143.
50. (b) Swanson, G. T., Gereau, R. W.; Green, T.; Heinemann, S. F. Identification of amino acid residues that control functional behavior in GluR5 and GluR6 kainate receptors. Neuron 1997, 19, 913-926.
51. Hogner, A.; Greenwood, J. R.; Liljefors, T.; Lunn, M.; Egebjerg, J.; Larsen, I. K., Gouaux, E.; Kastrup, J. S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. 2003, 46, 214-21.
52. Jin, R.; Banke, T. G.; Mayer, M. L.; Traynelis, S. F.; Gouaux, E. Structural basis for partial agonist action at ionotropic glutamate receptors. Nat. Neurosci. 2003, 6, 803-810.
53. Schoepp, D. D.; Lodge, D.; Bleakman, D.; Leander, J. D.; Tizzano, J. P.; Wright, R. A.; Palmer, A. J.; Salhoff, C. R.; Ornstein, P. L. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1-2H- tetrazole-5-yl)ethyl]decahydroisoquinoiline-3-carboxylic acid. Neuropharmacology 1995, 34, 1159-1168.
54. Bleakman, D.; Schoepp, D. D.; Ballyk, B.; Sharpe, E. F.; Bufton, H. R.; Thomas, K.; Ornstein, P. L.; Kamboj, R. K. Pharmacological discrimination of GluRS and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H- tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid. Mol. Pharmacol. 1996, 49, 581-585.
55. (a) Jones, K. A.; Wilding, T. J.; Huettner, J. E.; Costa, A. M. Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate. Neuropharmacology 1997, 36, 853-863.
56. (b) Zhou, L. M.; Gu, Z. Q.; Costa, A. M.; Yamada, K. A.; Mansson, P. E.; Giordano, T.; Skolnick, P.; Jones, K. A. (2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. J. Pharmacol. Exp. Ther. 1997, 280, 422-427.
57. Jones, S. C.; Troop, H. M.; Jane, D. E.; Roberts, P. J. Pharmacological characterization of novel AMPA receptor ligands in rat brain. Br. J. Pharmacol. 2001, 134, 145P.
58. Brehm, L.; Greenwood, J. R.; Hansen, K. B.; Nielsen, B.; Egebjerg, J.; Stensbøl, T. B.; Bräuner-Osborne, H.; Sløk, F. A.; Kronborg, T. T. A.; Povl Krogsgaard-Larsen, P. (S)-2-Amino-3-(3-hydroxy-7,8-dihydro-6H- cyclohepta[d]isoxazol-4-yl)propionic Acid, a potent and selective agonist at the GluR5 subtype of ionotropic glutamate receptors. Synthesis, modeling, and molecular pharmacology. J. Med. Chem. 2003, 46, 1350-1358.
59. Swanson, G. T.; Green, T.; Heinemann, S. F. Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol. Pharmacol. 1998, 53, 942-949.
60. Brown, D. J.; Hoerger, E.; Mason, S. F. Simple pyrimidines. Part II. 1:2-Dihydro-1-methylpyrimidines and the configuration of the N-methyluracils. J. Chem. Soc. 1955, 1, 211-217.
61. Singh, H.; Aggarwal, P.; Kumar, S. A facile synthesis of 1-monosubstituted and unsymmetrically 1,3-disubstituted uracils. Synthesis 1990, 520-522.
62. Barrett, H. W.; Goodman, I.; Dittmer, K. Synthesis of 5-halogeno-2-thiouracil and 6-methyl-5-halogeno-2-thiouracil derivatives. J. Am. Chem. Soc. 1948, 70, 1753-1756.
63. Ueda, T.; Fox, J. J. Pyrimidines. III. A novel rearrangement in the synthesis of imidazo-or pyrimido[1,2-c]pyrimidines. J. Org. Chem. 1964, 29, 1762-1769.
64. Novacek, A.; Lissnerova, M. Nucleic acid components and their analogues. CVII. Cyanoethylation of the uracil and 2-thiouracil derivatives. Collect. Czech. Chem. Commun. 1968, 33, 604-609.
65. Atkinson, M. R.; Maguire, M. H.; Ralph, R. K.; Shaw, G.; Warrener, R. N. Purines, pyrimidines and glyoxalines. Part V. New syntheses of uracils and orotic acids. J. Chem. Soc. 1957, 2, 2363-2368.
66. Evans, R. H.; Francis, A. A.; Jones, A. W.; Smith, D. A. S.; Watkins, J. C. The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br. J. Pharmacol. 1982, 75, 65-75.
67. Korczak, B.; Nutt, S. L.; Fletcher, E. J.; Hoo, K. H.; Elliott, C. E.; Rampersad, V.; McWhinnie, E. A.; Kamboj, R. K. cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. Recept. Channels 1995, 3, 41-49.
68. Hoo, K. H.; Nutt, S. L.; Fletcher, E. J.; Elliott, C. E.; Korczak, B.; Deverill, R. M.; Rampersad, V.; Fantaske, R. P.; Kamboj, R. K. Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit. Recept. Channels 1994, 2, 327-337.
69. Bleakman, D.; Ogden, A. M.; Ornstein, P. L.; Hoo, K. Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur. J. Pharmacol. 1999, 378, 331-337.
70. Paternain, A. V.; Rodriguez-Moreno, A.; Villarroel, A.; Lerma, J. Activation and desensitization properties of native and recombinant kainate receptors. Neuropharmacology 1998, 37, 1249-1259.
71. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
72. Alt, A.; Weiss, B.; Ogden, A. M.; Knauss, J. L.; Oler, J.; Ho, K.; Large, T. H.; Bleakman, D. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 2005, 46, 793-806.
73. Pook, P.; Brugger, F.; Hawkins, N. S.; Clark, K. C.; Watkins, J. C.; Evans, R. H. A comparison of the actions of agonists and antagonists at non-NMDA receptors of C fibres and motoneurones of the immature rat spinal cord in vitro. Br. J. Pharmacol. 1993, 108, 179-184.